Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study

Abstract Background In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial) treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin significantly reduced heart failure hospitalization (HHF) in patients with type 2 diabetes mellitus (T2D) and establi...

Descripció completa

Dades bibliogràfiques

Autors principals:	Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P. Keszei, Michael Böhm, Nikolaus Marx, Michael Lehrke
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2021-01-01
Col·lecció:	Cardiovascular Diabetology
Matèries:	SGLT2 inhibitors Diabetes Diastolic function Hemodynamic parameters
Accés en línia:	https://doi.org/10.1186/s12933-020-01175-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!